Advagene Biopharma Co. Ltd.
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. It engages in the development of nasal spray influenza vaccine; respiratory allergy treatment vaccine, including rhinitis and asthma; COVID-19 immunotherapy; and other vaccines. The company was founded in 2006 and is based in Taipei, Taiwan.
Advagene Biopharma Co. Ltd. (6709) - Total Liabilities
Latest total liabilities as of June 2025: NT$9.80 Million TWD
Based on the latest financial reports, Advagene Biopharma Co. Ltd. (6709) has total liabilities worth NT$9.80 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Advagene Biopharma Co. Ltd. - Total Liabilities Trend (2017–2024)
This chart illustrates how Advagene Biopharma Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Advagene Biopharma Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Advagene Biopharma Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NEOOTO Co. Ltd
KQ:212560
|
Korea | ₩70.52 Billion |
|
Jindal Poly Investment and Finance Company Limited
NSE:JPOLYINVST
|
India | ₹416.70 Million |
|
Budapesti Ingatlan Hasznositasi es Fejlesztesi Nyrt.
BUD:BIF
|
Hungary | Ft23.84 Billion |
|
Auric Mining Ltd
AU:AWJ
|
Australia | AU$2.05 Million |
|
Live Verdure Ltd
AU:LV1
|
Australia | AU$1.95 Million |
|
Molinos Juan Semino SA
BA:SEMI
|
Argentina | AR$13.45 Billion |
|
LTR Pharma Ltd
AU:LTP
|
Australia | AU$700.57K |
|
Spanish Mountain Gold Ltd.
OTCQB:SPAUF
|
USA | $1.60 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Advagene Biopharma Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Advagene Biopharma Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Advagene Biopharma Co. Ltd. (2017–2024)
The table below shows the annual total liabilities of Advagene Biopharma Co. Ltd. from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$11.67 Million | +46.35% |
| 2023-12-31 | NT$7.97 Million | -12.16% |
| 2022-12-31 | NT$9.08 Million | -16.26% |
| 2021-12-31 | NT$10.84 Million | -35.99% |
| 2020-12-31 | NT$16.93 Million | +115.64% |
| 2019-12-31 | NT$7.85 Million | -33.90% |
| 2018-12-31 | NT$11.88 Million | -5.04% |
| 2017-12-31 | NT$12.51 Million | -- |